Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) – and ribonucleic acid (RNA) – based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened at $6.10 in last trading session, and closed at $6.18, trading in the range of $5.75 – $6.50. The stock showed a positive/negative weekly performance of 0.58%.
XOMA Corp (NASDAQ:XOMA) confirmed that gevokizumab, the Company’s IL-1 beta modulatingantibody, has been granted Orphan Drug Designation by the U.S. Food& Drug Administration (:FDA) for the treatment of pyodermagangrenosum. XOMA Corp (NASDAQ:XOMA) shares closed at $8.85 on last trade day, by gaining 4.36%. Stock 52 week range is $2.46 – $9.13. Company’s market capitalization is $917.09 billion.
TheStreet Quant Ratings rates ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) as a sell. The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock decreased -2.43% and finished the last session at $28.14. The EPS of the stock remained -0.42. Company’s market capitalization is $2.56 billion.
Zacks reiterated their neutral rating on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) in a research report released on Friday morning, Analyst RN reports. Zacks currently has a $68.00 price objective on the stock. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) stock opened at $77.50 in last trading session and closed at $79.46. The 52 week range of the stock is $26.80 – $80.15 and the day range was $77.00 – $80.15.